Efficacy and Safety of ABT-874 in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Exclusion Criteria

• •Subject had previously received systemic or biologic anti-IL-12 therapy
• •Subject cannot discontinue systemic therapies and/or topical therapies for the treatment of psoriasis and cannot avoid UVB or PUVA phototherapy
• •Subject is taking or requires oral or injectable corticosteroids
• •Subject considered by the investigator, for any reason, to be an unsuitable candidate for the study
• •Female subject who is pregnant or breast-feeding or considering becoming pregnant